Biogen witnessed a 4% year over year drop in its top-line in the last quarter as Tecifidera revenue continued to erode in the U.S. due to generic entry. In light of several recent challenges, the company announced that it would implement cost-cutting measures expected to save approximately $500 million annually. On the other hand, they recently announced a deal to sell their Samsung Bioepis joint venture stake to Samsung Biologics, with Biogen continuing to be the commercialization partner for t ....
03 Mar 2022
Biogen Inc.: Financial & Price Forecasts, DCF Valuation, ESG & Other Risks (03/22)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Biogen Inc.: Financial & Price Forecasts, DCF Valuation, ESG & Other Risks (03/22)
- Published:
03 Mar 2022 -
Author:
Ishan Majumdar -
Pages:
16
Biogen witnessed a 4% year over year drop in its top-line in the last quarter as Tecifidera revenue continued to erode in the U.S. due to generic entry. In light of several recent challenges, the company announced that it would implement cost-cutting measures expected to save approximately $500 million annually. On the other hand, they recently announced a deal to sell their Samsung Bioepis joint venture stake to Samsung Biologics, with Biogen continuing to be the commercialization partner for t ....